Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ]: Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
Thu, September 2, 2010
Wed, September 1, 2010
Tue, August 31, 2010
Mon, August 30, 2010
Sun, August 29, 2010
Fri, August 27, 2010
[ Fri, Aug 27th 2010 ]: Market Wire
?????????????????????
Thu, August 26, 2010
Wed, August 25, 2010
Tue, August 24, 2010
Mon, August 23, 2010
Fri, August 20, 2010
Thu, August 19, 2010
Wed, August 18, 2010
Tue, August 17, 2010
Mon, August 16, 2010
Fri, August 13, 2010

Covidien Completes Sale of Specialty Chemicals Business


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. pletes-sale-of-specialty-chemicals-business.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

DUBLIN--([ BUSINESS WIRE ])--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced sale of its Specialty Chemicals business to an affiliate of New Mountain Capital, L.L.C. for a cash purchase price of approximately $280 million.

The decision to divest Specialty Chemicals was made following a thorough evaluation of a number of strategic alternatives. The decision is consistent with Covidiena™s strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the Company has or can develop a global competitive advantage.

The business is currently reported as a discontinued operation and the transaction is not expected to have a material effect on Covidiena™s operating income or earnings per share for fiscal 2010 or 2011.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2009 revenue of $10.3 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit [ www.covidien.com ] to learn more about our business.


Publication Contributing Sources